Search

Your search keyword '"Gaujoux-Viala, Cécile"' showing total 174 results
Start Over Author "Gaujoux-Viala, Cécile" Language english
174 results on '"Gaujoux-Viala, Cécile"'

2. 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis

Author

Fautrel, Bruno, Kedra, Joanna, Rempenault, Claire, Juge, Pierre-Antoine, Drouet, Juliette, Avouac, Jérôme, Baillet, Athan, Brocq, Olivier, Alegria, Guillermo Carvajal, Constantin, Arnaud, Dernis, Emmanuelle, Gaujoux-Viala, Cécile, Goëb, Vincent, Gottenberg, Jacques-Eric, Le Goff, Benoit, Marotte, Hubert, Richez, Christophe, Salmon, Jean-Hugues, Saraux, Alain, Senbel, Eric, Seror, Raphaèle, Tournadre, Anne, Vittecoq, Olivier, Escaffre, Pascale, Vacher, Danielle, Dieudé, Philippe, and Daien, Claire

Published
2024
Full Text
View/download PDF

11. Conventional radiography in juvenile idiopathic arthritis: Joint recommendations from the French societies for rheumatology, radiology and paediatric rheumatology

Author

Marteau, Pauline, Adamsbaum, Catherine, Rossi-Semerano, Linda, De Bandt, Michel, Lemelle, Irène, Deslandre, Chantal, Tran, Tu Anh, Lohse, Anne, Solau-Gervais, Elisabeth, Sordet, Christelle, Pillet, Pascal, Bader-Meunier, Brigitte, Wipff, Julien, Gaujoux-Viala, Cécile, Breton, Sylvain, and Devauchelle-Pensec, Valérie

Published
2018
Full Text
View/download PDF

19. Abatacept therapy and safety management

Author

Pham, Thao, Bachelez, Hervé, Berthelot, Jean-Marie, Blacher, Jacques, Claudepierre, Pascal, Constantin, Arnaud, Fautrel, Bruno, Gaujoux-Viala, Cécile, Goëb, Vincent, Gossec, Laure, Goupille, Philippe, Guillaume-Czitrom, Séverine, Hachulla, Eric, Lequerré, Thierry, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Mouthon, Luc, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Soubrier, Martin, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, Mariette, Xavier, and Sibilia, Jean

Published
2012
Full Text
View/download PDF

24. Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta‐Analysis.

Author

Wetzman, Amélie, Lukas, Cédric, Gaujoux‐Viala, Cécile, Mamtani, Ronac, Barnetche, Thomas, Combe, Bernard, Morel, Jacques, and Szafors, Paulina

Subjects
RHEUMATOID arthritis, DISEASE risk factors, TUMOR necrosis factors, ANTIRHEUMATIC agents, PSORIATIC arthritis
Abstract

Objective: To determine the risk of recurrent or new malignancy with exposure to targeted disease‐modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA) and a history of cancer. Methods: We performed a systematic search of the literature for articles published up to June 2019 that investigated adults with RA, axial SpA, or PsA who had a history of cancer and received biologic or targeted synthetic DMARDs (bDMARDs or tsDMARDs). We compared the risk of relapse or occurrence of new cancer between patients with and without bDMARDs. Rate ratios (RRs) with 95% confidence intervals (95% CIs) were estimated. The heterogeneity of the studies was evaluated by the Cochran Q test and the I2 statistic. Results: We included 24 observational studies of chronic inflammatory arthritis; of those, 12 were included in the meta‐analysis of RA patients receiving bDMARDs. As compared with RA patients with a history of cancer and not receiving bDMARDs, for those receiving any bDMARD, the overall RR for risk of neoplasia was 1.09 (95% CI 0.92–1.32; P = 0.31, I2 = 8%); with tumor necrosis factor inhibitors, it was 1.11 (95% CI 0.85–1.46; P = 0.45, I2 = 48%); and with rituximab, it was 0.79 (95% CI 0.41–1.53; P = 0.49, I2 = 0%). The RR for risk of recurrence for skin cancer was 1.32 (95% CI 1.02–1.72; P = 0.04, I2 = 0%) and for breast neoplasia 1.21 (95% CI 0.84–1.72; P = 0.31, I2 = 0%). Conclusion: Apart from skin cancers including melanoma, the risk of recurrent or new cancer is not increased with the initiation of bDMARDs for RA as compared with no bDMARDs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Patient Global Assessment of Disease Activity and Radiographic Progression in Early Arthritis: Three-Year Results From the ESPOIR Cohort.

Author

Ferreira, Ricardo J. O., Fautrel, Bruno, Saraux, Alain, Gaujoux‐Viala, Cécile, Rat, Anne‐Christine, Guillemin, Francis, da Silva, José A. P., Dougados, Maxime, Gossec, Laure, Gaujoux-Viala, Cécile, and Rat, Anne-Christine

Subjects
DISEASE progression, DISEASE remission, ARTHRITIS diagnosis, TREATMENT of arthritis, ARTHRITIS patients
Abstract

Objective: To determine whether patient global assessment of disease activity (PtGA) over the first year of disease course, as part of a Boolean-based definition of remission and considered individually, had a significant relationship with structural progression over 3 years in patients with early arthritis.Methods: We conducted a prospective, observational study using ESPOIR (Étude et Suivi des Polyarthrites Indifférenciées Récentes) cohort data. Remission states were defined as 1) 4-variable remission, which included a tender joint count in 28 joints, a swollen joint count in 28 joints (SJC28), a C-reactive protein (CRP; mg/dl) level, and PtGA (scored 0-10, all scores of ≤1); 2) PtGA near remission, which included the same parameters as 4-variable remission with only PtGA >1 (of a maximum possible score of 10); 3) 3-variable remission (sum of the proportion of patients in 4-variable remission and the proportion of patients in PtGA near remission); or 4) nonremission. The strictest status satisfied both at 6 and 12 months was considered. Radiographic progression was determined as a change of ≥5 points in the total Sharp/van der Heijde score (ΔSHS) from baseline to 3 years. The predictive capacities for radiographic damage of different remission definitions were assessed by odds ratio (OR). The association between each individual component of remission with ΔSHS was tested through multivariate linear regression analyses.Results: Among 520 patients, 7% achieved 4-variable remission and 12% achieved PtGA near remission. Radiographic progression was observed in 29% of patients who achieved 4-variable remission (OR versus nonremission; OR 0.32 [95% confidence interval (95% CI) 0.15, 0.68]) and in 45% of patients with PtGA near remission (OR 0.65 [95% CI 0.38, 1.11]); the comparison was not statistically different (OR 0.49 [95% CI 0.20, 1.18]). In 3-variable remission, radiographic progression was observed in 39%. Of the individual components, only the SJC28 and CRP level were associated with radiographic progression.Conclusion: All definitions of remission led to low structural degradation in early arthritis, and 4-variable remission led to less radiographic progression than PtGA near remission, but without a statistically significant difference. Both 4-variable remission and 3-variable remission appear to be useful targets when aiming for structural nonprogression. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, Josef S, Landewé, Robert, Breedveld, Ferdinand C, Buch, Maya, Burmester, Gerd, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cécile, Gossec, Laure, Nam, Jackie, Ramiro, Sofia, Winthrop, Kevin, de Wit, Maarten, Aletaha, Daniel, Betteridge, Neil, Bijlsma, Johannes W J, Boers, Maarten, Buttgereit, Frank, Combe, Bernard, Cutolo, Maurizio, Damjanov, Nemanja, Hazes, Johanna M W, Kouloumas, Marios, Kvien, Tore K, Mariette, Xavier, Pavelka, Karel, van Riel, Piet L C M, Rubbert-Roth, Andrea, Scholte-Voshaar, Marieke, Scott, David L, Sokka-Isler, Tuulikki, Wong, John B, and van der Heijde, Désirée

Published
2014
Full Text
View/download PDF

32. Patient global assessment and radiographic progression in early arthritis: 3‐year results from the ESPOIR cohort

Author

Ferreira, Ricardo J.O., Fautrel, Bruno, Saraux, Alain, Gaujoux‐Viala, Cécile, Rat, Anne‐Christine, Guillemin, Francis, Da Silva, José A.P., Dougados, Maxime, Gossec, Laure, Health Sciences Research Unit: Nursing [Coimbra, Portugal] (UICiSA:E), Escola Superior de Enfermagem de Coimbra [Coimbra, Portugal], Department of Rheumatology (COIMBRA - Rhumato), Universidade de Coimbra [Coimbra], Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CRI-IMIDIATE Clinical Research Network, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Service de Rhumatologie [CHRU Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Rhumatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Faculty of Medicine, University of Coimbra, 3000, Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipe 2 : ECSTRA - Epidémiologie Clinique, STatistique, pour la Recherche en Santé (CRESS - U1153), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), and Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
Quality of life, Predictive Value of Tests, Remission, Patient-reported Outcomes, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Rheumatoid arthritis, Structural damage, Patient global assessment
Abstract

International audience; Objectives: To determine if patient global assessment (PGA), as part of Boolean-based definition of remission and individually considered, over the first year of disease course had a significant relationship with structural progression over 3 years in patients with early arthritis (EA).Methods: Prospective, observational study using ESPOIR cohort data. Remission states were defined as (a) 4v-remission: tender (TJC28), swollen 28-joint counts (SJC28), C-Reactive protein (mg/dL), and PGA (0-10) all ≤1; (b) PGA-near-remission: same parameters with only PGA>1/10; (c) 3v-remission (sum of previous groups) or (d) non-remission. The strictest status satisfied both at 6- and 12-months was considered. Radiographic progression was determined as a change in total Sharp-van der Heijde score from baseline to 3 years (ΔSHS) ≥5 points. The predictive capacities for radiographic damage of different remission definitions were assessed by Odds Ratio (OR). The association between each individual component of remission with ΔSHS was tested through multivariate linear regression analyses.Results: Among 520 patients, 7% achieved 4v-remission and 12% PGA-near-remission. Radiographic progression was observed in 29% of patients in 4v-remission (OR versus non-remission, OR=0.32 [95%CI:0.15-0.68]) and in 45% of patients in PGA-near-remission (OR=0.65 [0.38-1.11]); the comparison was not statistically different (OR=0.49 [0.20-1.18]). In 3v-remission it was observed in 39%. Of the individual components, only SJC28 and CRP were associated with radiographic progression.Conclusion: All definitions of remission led to low structural degradation in EA: 4v-remission led to less progression than PGA-near-remission but without a statistically significant difference. Both 4v-remission and 3v-remission appear useful targets when aiming at structural non-progression.

Published
2020
Full Text
View/download PDF

40. Determinants of the Physician Global Assessment of Disease Activity and Influence of Contextual Factors in Early Axial Spondyloarthritis.

Author

Hirano, Fumio, Landewé, Robert B. M., van Gaalen, Floris A., van der Heijde, Désirée, Gaujoux‐Viala, Cécile, and Ramiro, Sofia

Subjects
SPONDYLOARTHROPATHIES, CONTEXTUAL analysis, ARTHRITIS, LONGITUDINAL method
Abstract

Objective: To investigate determinants of the physician global assessment (PhGA) of disease activity and the influence of the contextual factors on this relationship in patients with early axial spondyloarthritis (SpA). Methods: Five‐year data of DESIR, a cohort of early axial SpA, were analyzed. Univariable generalized estimating equations (GEEs) were used to investigate contributory explanatory effects of various potential determinants of PhGA. Effect modification by contextual factors (age, sex, and educational level) was tested, and if significant, models were stratified. Autoregressive GEE models (i.e., models adjusted for PhGA at the previous time point) were used to confirm a longitudinal relationship. Results: A total of 708 patients were included. Higher Bath Ankylosing Spondylitis Disease Activity Index individual questions, swollen joint count in 28 joints (SJC28), tender joint count in 53 joints, Maastricht Ankylosing Spondylitis Enthesitis Score, C‐reactive protein (CRP) level, and Bath Ankylosing Spondylitis Metrology Index score were associated with a higher PhGA. Sex and age were effect modifiers of SJC28; the contributory effect of SJC28 was largest in the younger male stratum (β = 1.07 [95% confidence interval (95% CI) 0.71, 1.43]), and the smallest in the older female stratum (β = 0.13 [95% CI 0.04, 0.22]). Autoregressive GEE models revealed the same determinants as having a longitudinal association with PhGA and the same pattern of effect modification. Conclusion: Patients' subjective symptoms, peripheral arthritis and enthesitis, higher CRP level, and impaired spinal mobility contribute to explaining PhGA in patients with early axial SpA, irrespective of sex and age. Intriguingly, physicians consider the presence of swollen joints as more important in males than in females. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission

Author

Joanna, KEDRA, Dieudé, Philippe, Marotte, Hubert, Lafourcade, Alexandre, Ducourau, Emilie, Schaeverbeke, Thierry, Perdriger, Aleth, Soubrier, Martin, Morel, Jacques, Constantin, Arnaud, Dernis, Emmanuelle, Royant, Valérie, Salmon, Jean-Hugues, Pham, Thao, Gottenberg, Jacques-Eric, Pertuiset, Edouard, Dougados, Maxime, Devauchelle-Pensec, Valérie, Gaudin, Philippe, Cormier, Gregoire, Goupille, Philippe, Mariette, Xavier, Berenbaum, Francis, Alcaix, Didier, Rouidi, Sid Ahmed, Berthelot, Jean-Marie, Monnier, Agnès, Piroth, Christine, Liote, Frederic, Goeb, Vincent, Gaujoux-Viala, Cécile, Valckenaere, Isabelle Chary, Hajage, David, Tubach, Florence, Fautrel, Bruno, Service de Rhumatologie [CHU Pitié Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sorbonne Université (SU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), INSERM U1059, SAINBIOSE - Santé, Ingénierie, Biologie, Saint-Etienne (SAINBIOSE-ENSMSE), Centre Ingénierie et Santé (CIS-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CRI-IMIDIATE Clinical Research Network, Service de Rhumatologie [Orléans], Centre Hospitalier Régional d'Orléans (CHRO), Composantes innées de la réponse immunitaire et différenciation (CIRID), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [Rennes] = Rheumatology [Rennes], CHU Pontchaillou [Rennes], Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service de Rhumatologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Rhumatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Hôpital Louis Pasteur [Chartres], Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Rhumatologie [Sainte- Marguerite - APHM] ( Hôpitaux Sud), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Hopital Réné Dubos, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe de Recherche et d'Etude du Processus Inflammatoire (GREPI), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Bicêtre, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Victor Jousselin de Dreux, Service de rhumatologie [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Rhumatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques (BIOSCAR (UMR_S_1132 / U1132)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lariboisière-Fernand-Widal [APHP], Service de Rhumatologie - AMIENS (AMIENS - Rhumato), CHU Amiens-Picardie, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM ), DESSAIVRE, Louise, Michel, Geneviève, Service de Rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-PRES Sorbonne Paris Cité, Department of Internal Medicine/Division of Rheumatology, University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Université de Tours, CHU Bordeaux [Bordeaux], Service de rhumatologie [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, School of Informatics [Edimbourg], University of Edinburgh, Service de rhumatologie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Groupe de Recherche et d’Étude du Processus Inflammatoire (GREPI), Université Joseph Fourier - Grenoble 1 (UJF)-EFS, Centre Hospitalier Départemental Vendée, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Département d'épidémiologie, biostatistique et recherche clinique, Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7)-PRES Sorbonne Paris Cité-AP-HP, CHU Clermont-Ferrand-Hôpital Gabriel Montpied, Service de Rhumatologie - CH Le Mans, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Groupe de Recherche et d'Etudes du Processus Inflammatoire (GREPI), Université Joseph Fourier - Grenoble 1 (UJF), Service de rhumatologie [Tours], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Service de rhumatologie, inflammation-immunopathologie- biothérapie [CHU Saint-Antoine] (DHU i2B ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Hôpital Lariboisière, Service de rhumatologie [Rouen], AP-HP Hôpital universitaire Robert-Debré [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Service de Rhumatologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université de Tours (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Santé Ingénierie Biologie Saint-Etienne (SAINBIOSE), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de Rhumatologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest-Institut Brestois Santé Agro Matière (IBSAM), and Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris]

Subjects
[SDV] Life Sciences [q-bio], [SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV]Life Sciences [q-bio], [SDV.IMM]Life Sciences [q-bio]/Immunology, ComputingMilieux_MISCELLANEOUS
Abstract

Annual European Congress of Rheumatology (EULAR), Madrid, SPAIN, JUN 12-15, 2019; International audience

Published
2019
Full Text
View/download PDF

42. MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE.

Author

Gaujoux-Viala, Cécile, Hudry, Christophe, Zinovieva, Elena, Herman-Demars, Hélène, and Flipo, René-Marc

Subjects
*RESEARCH, *PATIENT aftercare, *BIOLOGICAL products, *SCIENTIFIC observation, *ORAL drug administration, *FUNCTIONAL status, *MEDICAL cooperation, *METHOTREXATE, *ANTIRHEUMATIC agents, *TREATMENT effectiveness, *RHEUMATOID arthritis, *DISEASE susceptibility, *DESCRIPTIVE statistics, *SYMPTOMS, *DRUG side effects, *LONGITUDINAL method, *PROBABILITY theory
Abstract

Objectives The STRATEGE (Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis) study aimed to describe treatment strategies in current practice in RA biologic DMARD (bDMARD)-naïve patients with an inadequate response to MTX therapy, and to compare clinical efficacy of the different therapeutic strategies on disease activity after 6 months. Methods The main inclusion criteria of this prospective, observational, multicentre study were confirmed RA diagnosis, treatment by MTX monotherapy and need for therapeutic management modification. Results The 722 patients included had a mean (s. d.) RA duration of 5.3 (6.7) years, a mean DAS28 of 4.0 (1.1); they were all receiving MTX monotherapy, 68% oral, at a mean dose of 15.0 (4.1) mg/week. Two major strategies were identified: (i) MTX monotherapy dose and/or route optimization (72%) and (ii) bDMARD initiation ± MTX (16%). MTX dosing was modified for 70% of patients, maintained (dose and route) for 28% of patients and interrupted for 2%. bDMARDs were started when the MTX mean dose was 17.4 mg/week, 56% parenterally; MTX was maintained concomitantly for 96% of patients. Six-month follow-up results adjusted by propensity score showed that both options were equally successful in improving disease activity and physical function, with 63 and 68% of good-to-moderate EULAR responses, respectively. Conclusion The STRATEGE study shows the importance of initial MTX treatment optimization before initiation of a biological treatment and emphasizes the importance of treat-to-target strategy. Trial registration ClinicalTrials.gov NCT02288520. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index.

Author

Bykerk, Vivian P., Blauvelt, Andrew, Curtis, Jeffrey R., Gaujoux‐Viala, Cécile, Kvien, Tore K., Winthrop, Kevin, Tilt, Nicola, Popova, Christina, Mariette, Xavier, and Haraoui, Boulos

Subjects
BODY mass index, CORTICOSTEROIDS, ADVERSE health care events, RHEUMATOID arthritis, PATIENT safety, PSORIATIC arthritis
Abstract

Objective: To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods: Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and plaque psoriasis (PSO). Cox proportional hazards modeling was used to investigate the association of baseline patient characteristics with risk of serious infectious events (SIEs), malignancies, and major adverse cardiac events (MACEs). Cox modeling for recurrent events assessed the impact of time‐varying body mass index (BMI), systemic corticosteroid (CS) use, and disease activity on SIE risk in RA and SAE risk in PSO. Results: Data were pooled from 8747 CZP‐treated patients across indications. Cox models reported a 44% increase in SIE risk associated with a baseline BMI of 35 kg/m2 or more versus a baseline BMI of 18.5 kg/m2 to less than 25 kg/m2. Baseline systemic CS use, age of 65 years or more, and disease duration of 10 years or longer also increased SIE risk. Older age was the only identified risk factor for malignancies. The risk of MACEs increased 107% for BMI of 35 kg/m2 or more versus BMI of 18.5 kg/m2 to less than 25 kg/m2 and increased 51% for men versus women. Higher disease activity, older age, systemic CS use, BMI of 35 kg/m2 or more, and baseline comorbidities were SIE risk factors in RA. Age and systemic CS use were risk factors for SAEs in PSO. Conclusion: Age, BMI, systemic CS use, and disease activity were identified as SIE risk factors in CZP‐treated patients. Risk of malignancies was greater in older patients, whereas obesity and male sex were MACE risk factors. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review.

Author

Rempenault, Claire, Combe, Bernard, Barnetche, Thomas, Gaujoux‐Viala, Cécile, Lukas, Cédric, Morel, Jacques, Hua, Charlotte, and Gaujoux-Viala, Cécile

Subjects
RHEUMATOID arthritis diagnosis, SYSTEMATIC reviews, ANTIRHEUMATIC agents, TREATMENT effectiveness, RHEUMATOID arthritis, HYDROXYCHLOROQUINE
Abstract

Objective: Hydroxychloroquine (HCQ) improves metabolic and cardiovascular outcomes in patients with rheumatoid arthritis (RA), but its efficacy appears to be moderate as compared to placebo. The aim of our study was to assess the current literature on the clinical and structural efficacy of HCQ in the joints of patients with RA.Methods: We systematically searched MEDLINE (via PubMed), Embase, Cochrane Library, and the American College of Rheumatology and European League Against Rheumatism annual scientific meeting abstracts for studies available up to November 2017 comparing the efficacy of HCQ in patients with RA, in monotherapy or combined with other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Data were extracted by 1 investigator and independently checked by a different investigator.Results: The literature search revealed 197 articles and abstracts of potential interest, and 11 studies fulfilled inclusion criteria. The clinical and structural efficacy of HCQ was similar to or lower than that for methotrexate or sulfasalazine in monotherapy. HCQ combined with other DMARDs could increase the clinical efficacy.Conclusion: In addition to its metabolic benefit, combining HCQ with other DMARDs could provide some clinical improvement in patients with RA and inadequate response to previous csDMARDs. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

45. Cardiovascular Morbidity and Mortality in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.

Author

Beltai, Aurélie, Barnetche, Thomas, Daien, Claire, Lukas, Cedric, Gaujoux‐Viala, Cécile, Combe, Bernard, Morel, Jacques, and Gaujoux-Viala, Cécile

Subjects
SURVIVAL, RESEARCH, META-analysis, RESEARCH methodology, ARTHRITIS Impact Measurement Scales, CARDIOVASCULAR diseases, DISEASES, WORLD health, EVALUATION research, MEDICAL cooperation, COMPARATIVE studies, SJOGREN'S syndrome, DISEASE complications
Abstract

Objective: Patients with immune-mediated inflammatory diseases such as rheumatoid arthritis or systemic lupus erythematosus are at increased risk of cardiovascular disease. However, the cardiovascular risk of patients with primary Sjögren's syndrome (SS) remains poorly studied. We aimed to investigate the association between primary SS and cardiovascular morbidity and mortality.Methods: We performed a systematic review of articles in Medline and the Cochrane Library and recent abstracts from US and European meetings, searching for reports of randomized controlled studies of cardiovascular morbidity and cardiovascular mortality in primary SS. The relative risk (RR) values for cardiovascular morbidity and mortality associated with primary SS were collected and pooled in a meta-analysis with a random-effects model by using Review Manager (Cochrane collaboration).Results: The literature search revealed 484 articles and abstracts of interest; 14 studies (67,124 patients with primary SS) were included in the meta-analysis. With primary SS versus control populations, the risk was significantly increased for coronary morbidity (RR 1.34 [95% confidence interval (95% CI) 1.06-1.38]; P = 0.01), cerebrovascular morbidity (RR 1.46 [95% CI 1.43-1.49]; P < 0.00001), heart failure rate (odds ratio 2.54 [95% CI 1.30-4.97]; P < 0.007), and thromboembolic morbidity (RR 1.78 [95% CI 1.41-2.25]; P < 0.00001), with no statistically significant increased risk of cardiovascular mortality (RR 1.48 [95% CI 0.77-2.85]; P = 0.24).Conclusion: This meta-analysis demonstrates that primary SS is associated with increased cardiovascular morbidity, which suggests that these patients should be screened for cardiovascular comorbidities and considered for preventive interventions, in a multidisciplinary approach with cardiologists. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

46. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.

Author

Decarriere, Guillaume, Barnetche, Thomas, Combe, Bernard, Gaujoux-Viala, Cécile, Lukas, Cédric, Morel, Jacques, and Daien, Claire

Subjects
RHEUMATOID arthritis treatment, ANTIRHEUMATIC agents, METHOTREXATE, RITUXIMAB, COMBINATION drug therapy, DRUG efficacy, MEDICATION safety, BIOTHERAPY, RHEUMATOID arthritis diagnosis, RESEARCH, BIOLOGICAL products, META-analysis, TIME, RESEARCH methodology, SYSTEMATIC reviews, MEDICAL cooperation, EVALUATION research, TREATMENT effectiveness, COMPARATIVE studies, RHEUMATOID arthritis, DRUG therapy
Abstract

Objective: In rheumatoid arthritis, the association between advanced therapies (including biologic disease-modifying antirheumatic drugs [DMARDs] and targeted synthetic DMARDs) and methotrexate (MTX) is recommended by international societies. When MTX cannot be used, other conventional synthetic DMARDs (csDMARDs) may be proposed. We aimed to compare the safety and efficacy of MTX and non-MTX csDMARDs in combination with advanced therapies.Methods: We systematically searched the literature for studies comparing the effectiveness, retention rate, and safety of MTX versus non-MTX csDMARDs (leflunomide or others) in combination with tumor necrosis factor inhibitors (TNFi), abatacept, rituximab, tocilizumab, and JAK inhibitors. Meta-analysis was performed with RevMan, using an inverse variance approach with fixed or random-effects models. Risk ratios (RRs) and 95% confidence intervals (95% CIs) were estimated.Results: The literature search revealed 3,842 articles; 41 studies were included for the systematic literature review and 21 for the meta-analysis: 13 with TNFi, 3 with abatacept, and 5 with rituximab. For TNFi, the European Alliance of Associations for Rheumatology (EULAR) response at 6 months was lower for patients receiving non-MTX csDMARDs than for those using MTX (RR 0.93 [95% CI 0.87, 1.0], P = 0.04; n = 3,843; I2 = 28%), with a lower retention rate at 12 months. For abatacept, effectiveness and safety were similar between the 2 groups. For rituximab, a good EULAR response was higher with leflunomide than MTX (RR 1.38 [95% CI 1.13, 1.68], P = 0.001; n = 2,078; I2 = 0%), with similar adverse event rates. Meta-analysis for tocilizumab or JAK inhibitors could not be performed.Conclusion: The different csDMARDs seem safe and efficient to combine with advanced therapies in RA patients. Although MTX seems slightly superior to other csDMARDs in combination with TNFi, leflunomide might be superior to MTX in combination with rituximab. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort.

Author

Hirano, Fumio, Heijde, Désirée van der, Gaalen, Floris A van, Landewé, Robert B M, Gaujoux-Viala, Cécile, and Ramiro, Sofia

Subjects
AGE distribution, BACKACHE, CONFIDENCE intervals, FATIGUE (Physiology), HEALTH attitudes, JOINT diseases, LIFE skills, QUALITY of life, SEX distribution, SPONDYLOARTHROPATHIES, DISABILITIES, SECONDARY analysis, WELL-being, EDUCATIONAL attainment, PATIENTS' attitudes, DESCRIPTIVE statistics
Abstract

Objectives To investigate the determinants of patient well-being over time, and the influence of age, gender and education in patients with early axial spondyloarthritis (axSpA). Methods Five-year data from DESIR, a cohort of early axSpA, were analysed. The outcome was the BAS-G over 5 years. Generalized estimating equations (GEE) were used to test the relationship between potential explanatory variables from five outcome domains (disease activity, physical function, spinal mobility, structural damage and axial inflammation) and BAS-G over time. Longitudinal relationships were analysed using an autoregressive GEE model. Age, gender and educational level were tested as effect modifiers or confounders. Results A total of 708 patients were included. Higher BASDAI questions on fatigue [β (95% CI): 0.17 (0.13, 0.22)], back pain [0.51 (0.46, 0.56)], peripheral joint pain [0.08 (0.04, 0.12)] and severity of morning stiffness [0.08 (0.03–0.13)], and higher BASFI [0.14 (0.08, 0.19)] were associated with a higher BAS-G. In the autoregressive model, the same variables except for morning stiffness were associated with a worsening in BAS-G. Age, gender and educational level were neither effect modifiers nor confounders. Conclusion A higher level of back pain is associated with a worsening of patient well-being, as are, though to a lesser extent, higher levels of fatigue, peripheral joint pain and physical disability. Age, gender and educational level do not have an impact on these relationships. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology

Author

Beyer, Christian, Ramiro, Sofia, Sivera, Francisca, Mandl, Peter, MacHado, Pedro M., Ospelt, Caroline, Moltó, Anna, Radner, Helga, Iagnocco, Annamaria, Bijlsma, Johannes W., Lundberg, Ingrid E., Grigoriou, Antigoni, Fanouriakis, Antonis, Hueber, Axel, Maurer, Britta, Scirè, Carlo A., Gaujoux-Viala, Cécile, Karpec, Diana, Van Der Woude, Diane, Rimar, Doron, Deseatnicova, Elena, Nikiphorou, Elena, De Langhe, Ellen, Haavardsholm, Espen A., Starodubtseva, Irina, Nagy, György, Biliavska, Iuliia V., Sznajd, Jan, Karlsson, Johan A., Zepa, Julija, Cassar, Karen, Šenolt, Ladislav, Ghukasyan, Liana, Barešić, Marko, Frank-Bertoncelj, Mojca, Ziade, Nelly, Gobejishvili, Nino, Ostojic, Predrag, Østgård, René, Dobrota, Rucsandra, Shumnalieva, Russka, Tälli, Sandra, Panchal, Sonia, Volpinari, Stefania, Rannio, Tuomas, Romão, Vasco C., Medizinische Universität Wien = Medical University of Vienna, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Université Paris Descartes - Paris 5 (UPD5), Hôpital Cochin [AP-HP], Université Sorbonne Paris Cité (USPC), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], University Medical Center [Utrecht], Karolinska Institutet [Stockholm], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Sapienza University [Rome], Beyer, C, Ramiro, S, Sivera, F, Mandl, P, Machado, P, Ospelt, C, Molto, A, Radner, H, Iagnocco, A, Bijlsma, J, Lundberg, I, Grigoriou, A, Fanouriakis, A, Hueber, A, Maurer, B, Scire, C, Gaujoux-Viala, C, Karpec, D, Van Der Woude, D, Rimar, D, Deseatnicova, E, Nikiphorou, E, De Langhe, E, Haavardsholm, E, Starodubtseva, I, Nagy, G, Biliavska, I, Sznajd, J, Karlsson, J, Zepa, J, Cassar, K, Senolt, L, Ghukasyan, L, Baresic, M, Frank-Bertoncelj, M, Ziade, N, Gobejishvili, N, Ostojic, P, Ostgard, R, Dobrota, R, Shumnalieva, R, Talli, S, Panchal, S, Volpinari, S, Rannio, T, Romao, V, Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)

Subjects
musculoskeletal diseases, medicine.medical_specialty, Immunology, education, Health services research, Magnetic Resonance Imaging, Ultrasonography, Rheumatology, Immunology and Allergy, Joint venture, Musculoskeletal ultrasound, League, Education, NO, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, 030212 general & internal medicine, 030203 arthritis & rheumatology, Modalities, business.industry, 4. Education, medicine.disease, Family medicine, Portfolio, business, Rheumatism, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; OBJECTIVES:To understand the educational needs and preferences of young clinicians and physician researchers in the field of rheumatology in Europe.METHODS:An international online survey was performed as a joint venture of ESCET and EMEUNET. The survey assessed the acceptance of and the access to the current European League Against Rheumatism (EULAR) educational portfolio, as well as the unmet educational needs and learning preferences among individuals below the age of 40 years working in rheumatology in Europe.RESULTS:Among 568 European clinicians and physician researchers, 65% indicated that the existing EULAR educational portfolio adequately covers their educational needs. Within the EULAR portfolio, the online course on rheumatic diseases and the postgraduate course were the most appreciated. Participants were very much in favour of new educational courses on imaging techniques, and 63% of participants indicated a particular interest in musculoskeletal ultrasound. A strong interest in refresher (60%) and general review (55%) courses was observed. Lack of funding was considered the major obstacle to participating in existing EULAR programmes. Finally, participants showed diverse preferences regarding learning modalities with common interests in live courses and conferences.CONCLUSIONS:EULAR's training opportunities are well appreciated among young clinicians and physician researchers in rheumatology. The results from this survey will help to develop EULAR's future educational portfolio.

Published
2016
Full Text
View/download PDF

49. Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross-Sectional Multicenter Study

Author

Couderc, Marion, Tatar, Zuzana, Pereira, Bruno, Tiple, Aurélien, Gilson, Mélanie, Fautrel, Bruno, Pouplin, Sophie, Dernis, Emmanuelle, Gossec, Laure, Gaujoux-Viala, Cécile, Soubrier, Martin, Dougados, Maxime, CHU Clermont-Ferrand, CHU Grenoble, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Rouen, Normandie Université (NU), Centre Hospitalier Le Mans (CH Le Mans), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université Sorbonne Paris Cité (USPC), and Herrada, Anthony

Subjects
Adult, Male, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Blood Sedimentation, Middle Aged, Risk Assessment, Severity of Illness Index, Arthritis, Rheumatoid, Proteinuria, Cross-Sectional Studies, Logistic Models, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Risk Factors, Hypertension, Multivariate Analysis, Odds Ratio, Prevalence, Humans, Female, Kidney Diseases, France, Aged, Glomerular Filtration Rate
Abstract

International audience; OBJECTIVE:To assess the prevalence and associations of renal dysfunction in patients with rheumatoid arthritis (RA).METHODS:COMEDRA is a French nationwide cross-sectional multicenter study on comorbidities in RA. Renal function was assessed from the estimated glomerular filtration rate (eGFR), using the Modification of Diet in Renal Disease equation. RA characteristics and risk factors for renal impairment were collected. Two logistic regression models, 1 with and 1 without the Framingham Risk Score, were constructed from variables that were significantly associated with an eGFR of

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results